The BET inhibitor JQ-1 promotes the infiltration of PD-1(+) CD8(+) T cells, CD4(+) T cells, and regulatory T (Treg) cells into TH-MYCN mouse neuroblastoma cells, and its combination with anti-PD-1 therapy can synergistically enhance the tumor inhibitory effect (Sauvage et al., 2022). Here, CD8A is linked to neuroblastoma.